Isoniazid for preventing tuberculosis in non-HIV infected persons. - sprookjes - yvandenbroek - TriplyDB

Isoniazid for preventing tuberculosis in non-HIV infected persons.

Isoniazid for preventing tuberculosis in non-HIV infected persons.

http://www.wikidata.org/entity/Q33900621

about

A three-way comparison of tuberculin skin testing, QuantiFERON-TB gold and T-SPOT.TB in children Directly observed therapy for treating tuberculosis Patient education and counselling for promoting adherence to treatment for tuberculosis Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB Isoniazid monotherapy versus other monotherapies or combination chemotherapy for preventing active tuberculosis in HIV-negative persons Recent developments in treatment of latent tuberculosis infection What can we offer to 3 million MDRTB household contacts in 2016?Controlling the seedbeds of tuberculosis: diagnosis and treatment of tuberculosis infection The ongoing challenge of latent tuberculosis Completion of treatment for latent tuberculosis infection with monthly drug dispensation directly through the tuberculosis clinic Novel M tuberculosis antigen-specific T-cells are early markers of infection and disease progression Effect of secondary preventive therapy on recurrence of tuberculosis in HIV-infected individuals: a systematic review.Screening for latent tuberculosis infection among undocumented immigrants in Swiss healthcare centres; a descriptive exploratory study.Accuracy of immunodiagnostic tests for active tuberculosis using single and combined results: a multicenter TBNET-Study.Different screening strategies (single or dual) for the diagnosis of suspected latent tuberculosis: a cost effectiveness analysis A randomized controlled study of socioeconomic support to enhance tuberculosis prevention and treatment, Peru.Pharmacokinetics of isoniazid in low-birth-weight and premature infants.Drug-resistant tuberculosis and advances in the treatment of childhood tuberculosis.Fatal Unusual Miliary Tuberculosis in which a Patient Developed Acute Respiratory Distress Syndrome Induced by Infliximab: An Autopsy Case Report.Kinetics of a tuberculosis-specific gamma interferon release assay in military personnel with a positive tuberculin skin test.Operational challenges in managing Isoniazid Preventive Therapy in child contacts: a high-burden setting perspective An evaluation of factors associated with taking and responding positive to the tuberculin skin test in individuals with HIV/AIDS.High caseload of childhood tuberculosis in hospitals on Java Island, Indonesia: a cross sectional study Closing the policy-practice gap in the management of child contacts of tuberculosis cases in developing countries.Contact investigation of children exposed to tuberculosis in South East Asia: a systematic review Changing concepts of "latent tuberculosis infection" in patients living with HIV infection.Diagnosis and treatment of latent tuberculosis infection: an update.Tuberculosis and illicit drug use: review and update.Impact of latent infection treatment in indigenous populations.Does an isoniazid prophylaxis register improve tuberculosis contact management in South African children?Efficacy of isoniazid prophylactic therapy in prevention of tuberculosis in children: a meta-analysis.Predictive value of interferon-gamma release assays for postpartum active tuberculosis in HIV-1-infected women Pregnancy differentially impacts performance of latent tuberculosis diagnostics in a high-burden setting.Modelling the performance of isoniazid preventive therapy for reducing tuberculosis in HIV endemic settings: the effects of network structure.Primary isoniazid prophylaxis against tuberculosis in HIV-exposed children Evidence-based clinical guidelines for immigrants and refugees.Tuberculosis: evidence review for newly arriving immigrants and refugees.Diagnosing latent tuberculosis in high-risk individuals: rising to the challenge in high-burden areas.Towards tuberculosis elimination: an action framework for low-incidence countries Close contact investigation of TB in high-burden, low- and middle-income countries.

P2860

Q21562599-2F01B346-42A5-40F5-81CA-B71ED59AFCBD Q24187767-A76F1422-68A9-479B-9247-BF3EC88BBF67 Q24197661-859092EF-625F-452F-B9FE-0B4AABFDAD79 Q24201325-9D33B25E-E354-4E46-BB43-21FE6C867B1B Q24240472-CEF0FB27-DC17-46FA-A7E9-EB8ED1C942E5 Q24630473-9C77F582-15D3-4310-931C-CB34330A0D4B Q28066845-C9B8F905-3B32-4BB4-92B1-22FF2BCF6BBC Q28087385-E079A283-C4DD-4694-AD80-62F15367FA22 Q28386135-8762D9E4-D252-421A-AC4F-C1DC975FBB7B Q28484855-6C7A3F02-FEB7-4F8C-9716-EA1B987DF769 Q28740799-FAC1C7EB-9586-49CB-9CD0-939A9E8F8512 Q30240445-FFFE1928-F5E1-45D5-A7AA-E98983C49AEC Q30859922-D338C6D7-FC5B-4920-90C5-FF2B5066F1FD Q33377055-62909CD9-E955-44BC-A6C3-F17393B59C4E Q33532816-6589A72F-9072-428B-93E6-5E33E5FDFFBE Q33609582-6572A6FC-C93E-4A59-AD92-E823A1723DBB Q33622922-6DA50947-756E-4BB1-973D-FAC6D12B1B62 Q33801345-9B0A8A7C-6B8E-4EC2-B174-018E578F55AA Q33818727-E1A7A5FF-C302-46E3-9FB2-E12E194DABFA Q33909191-80BEADD7-67A6-4541-B93B-DEDD0EA0DB3C Q33955943-1174B639-9B6E-4FBB-9E32-EF35D5D5D204 Q34011244-D07126E6-B423-40F7-B096-E9B30E27BCC5 Q34045423-7E19F280-3B6A-4668-8EE2-F00F3F3B3EEC Q34055185-F5027013-AF1D-493D-A8B1-7D6D71572932 Q34102809-D3360CAC-43B8-43E0-B457-11A238F2469E Q34170017-D81E88C2-97ED-49B1-813C-7284EB075FA0 Q34290177-2649853D-72A0-44A3-A2FE-D4C23401C754 Q34601143-72A178D1-2A08-4F61-AB6C-E506E546D6D7 Q34923710-560D39B5-8711-45D1-9D41-9A4B0EBF00D0 Q35067349-C3B47109-0745-49CC-946F-82BE7514072C Q35098753-2787C369-7DDF-4365-9F54-9A586B8BF9AC Q35118980-33BF7A02-20BA-4464-A622-9614394048AD Q35127992-2B052697-953F-49A4-9E97-B6BEEE0F5C64 Q35185440-A2DD0AAB-E012-4500-BE16-9D60A14BB1C0 Q35188837-80275ED0-ECCB-4542-B702-00E4B0DB19BD Q35201293-FBA7519B-DC0C-42F9-A593-52AADF222FF3 Q35201314-4E3BAC8F-21D9-4D76-8C7B-2BCAFA2DCD88 Q35336540-F47C0AA2-260F-415D-AAA6-B016D9A8C6C8 Q35344151-C5037017-41E5-4DF1-B67C-D9C1D4A7B4CA Q35443130-8E4E8B60-F49D-419A-9763-ED062ED87504

P2860

Isoniazid for preventing tuberculosis in non-HIV infected persons.

http://www.wikidata.org/entity/Q33900621

description

2000 nî lūn-bûn

@nan

2000 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2000 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2000年の論文

@ja

2000年論文

@yue

2000年論文

@zh-hant

2000年論文

@zh-hk

2000年論文

@zh-mo

2000年論文

@zh-tw

2000年论文

@wuu

name

Isoniazid for preventing tuberculosis in non-HIV infected persons.

@ast

Isoniazid for preventing tuberculosis in non-HIV infected persons.

@en

type

label

Isoniazid for preventing tuberculosis in non-HIV infected persons.

@ast

Isoniazid for preventing tuberculosis in non-HIV infected persons.

@en

prefLabel

Isoniazid for preventing tuberculosis in non-HIV infected persons.

@ast

Isoniazid for preventing tuberculosis in non-HIV infected persons.

@en

P1433

Q33900621-91D88CD8-95D9-45E3-8C5E-8DC03309183A

P1476

Q33900621-EE65281D-02F0-4FCC-A3F2-2B68FB6C6731

P2093

Q33900621-1D444BE2-2AB4-449A-8F9B-B8B66BFD9A66

Q33900621-4656285F-958E-4153-9727-C2DE15C75946

Q33900621-52E70CD5-C222-44BD-8C0F-E17AFDD9075A

Q33900621-E3DC70FB-A53B-4B56-B833-BE0F605B49B8

P2860

Q33900621-0178873E-41E0-4798-BD7F-5B2AA44EFB7C

Q33900621-041754A9-7C23-44D2-B0CD-46C7701F9B4B

Q33900621-075D7ADE-909C-42FD-96CB-82600FA59EBB

Q33900621-0FD1677F-3B5F-4BF0-A106-9A5FE30CA853

Q33900621-3BCFC08F-92A1-4EBC-950D-BC84C64D8AD7

Q33900621-3FD9BA53-195C-4106-B10F-36746DF544BF

Q33900621-435DE5FF-7D53-415E-BDA2-2BD65EB1B798

Q33900621-614B596B-F3E2-4027-9413-1DCBEE296868

Q33900621-6FC931C5-4941-4472-BA1B-32E670E67BE1

Q33900621-7058DC1B-74D0-4550-B3EB-B1730B9343FE

P304

Q33900621-7B7C303B-7DDD-45E5-8E91-768A50BE7C2C

P31

Q33900621-08DCB51C-E88C-4ECB-8E9A-8CEC8548F353

P356

Q33900621-E7E182A5-18B9-4B86-9BBD-17D01B8F1736

P433

Q33900621-8575175A-C233-4A14-9CE4-AEF0E87D63CB

P577

Q33900621-E54A7AF1-15BF-44E0-86FD-70EA79B18BEC

P698

Q33900621-97BE518B-F27C-4352-BE8E-E4384362E379

P921

Q33900621-A3CA7694-96A3-43A3-BAD0-805586A839EA

P932

Q33900621-E248BAE5-C071-433A-B6CE-830CCE84E9AD

P356

14651858.CD001363

P1433

Cochrane Database of Systematic Reviews

P1476

Isoniazid for preventing tuberculosis in non-HIV infected persons.

@en

P2093

C A Marchetti

http://www.w3.org/2001/XMLSchema#string

D J Cook

http://www.w3.org/2001/XMLSchema#string

F M Smaill

http://www.w3.org/2001/XMLSchema#string

M J Smieja

http://www.w3.org/2001/XMLSchema#string

P2860

An assessment of clinically useful measures of the consequences of treatment

Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society and The Centers for Disease Control and Prevention.

Isoniazid-associated hepatitis deaths: a review of available information.

A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration.

Isoniazid preventive therapy for tuberculosis in HIV-1-infected adults: results of a randomized controlled trial.

Prophylaxis with isoniazid in inactive tuberculosis. A Veterans Administration Cooperative Study XII.

Tuberculosis in the 1990s.

Using numerical results from systematic reviews in clinical practice.

Isoniazid preventive therapy for tuberculosis. Decision analysis considering ethnicity and gender.

Benefit-risk considerations in preventive treatment for tuberculosis in elderly persons.

P304

CD001363

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/14651858.CD001363

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P577

2000-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

10796642

http://www.w3.org/2001/XMLSchema#string

P921

Akafuba bulwadde

P932

6532737

http://www.w3.org/2001/XMLSchema#string